Display options
Cite
Campennì A, Giovanella L, Pignata SA, et al. Undetectable or low (<1 ng/ml) postsurgical thyroglobulin values do not rule out metastases in early stage differentiated thyroid cancer patients. Oncotarget. 2018;9(25):17491-17500doi: 10.18632/oncotarget.24766.
Campennì, A., Giovanella, L., Pignata, S. A., Vento, A., Alibrandi, A., Sturiale, L., Laudicella, R., Comis, A. D., Filice, R., Giuffrida, G., Stipo, M. E., Giovinazzo, S., Trimarchi, F., Ruggeri, R. M., & Baldari, S. (2018). Undetectable or low (<1 ng/ml) postsurgical thyroglobulin values do not rule out metastases in early stage differentiated thyroid cancer patients. Oncotarget, 9(25), 17491-17500. https://doi.org/10.18632/oncotarget.24766
Campennì, Alfredo, et al. "Undetectable or low (<1 ng/ml) postsurgical thyroglobulin values do not rule out metastases in early stage differentiated thyroid cancer patients." Oncotarget vol. 9,25 (2018): 17491-17500. doi: https://doi.org/10.18632/oncotarget.24766
Campennì A, Giovanella L, Pignata SA, Vento A, Alibrandi A, Sturiale L, Laudicella R, Comis AD, Filice R, Giuffrida G, Stipo ME, Giovinazzo S, Trimarchi F, Ruggeri RM, Baldari S. Undetectable or low (<1 ng/ml) postsurgical thyroglobulin values do not rule out metastases in early stage differentiated thyroid cancer patients. Oncotarget. 2018 Apr 03;9(25):17491-17500. doi: 10.18632/oncotarget.24766. eCollection 2018 Apr 03. PMID: 29707123; PMCID: PMC5915131.
Copy Download .nbib Format: NLM
Share it on

Oncotarget. 2018 Apr 03;9(25):17491-17500. doi: 10.18632/oncotarget.24766. eCollection 2018 Apr 03.

Undetectable or low (<1 ng/ml) postsurgical thyroglobulin values do not rule out metastases in early stage differentiated thyroid cancer patients.

Oncotarget

Alfredo Campennì, Luca Giovanella, Salvatore Antonio Pignata, Antonio Vento, Angela Alibrandi, Letterio Sturiale, Riccardo Laudicella, Alessio Danilo Comis, Rossella Filice, Giuseppe Giuffrida, Maria Elena Stipo, Salvatore Giovinazzo, Francesco Trimarchi, Rosaria Maddalena Ruggeri, Sergio Baldari

Affiliations

  1. Department of Biomedical and Dental Sciences and Morpho-Functional Imaging, Nuclear Medicine Unit, University of Messina, Messina, Italy.
  2. Nuclear Medicine and PET/CT Centre, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland.
  3. Department of Economical, Business and Environmental Sciences and Quantitative Methods, University of Messina, Messina, Italy.
  4. Department of Clinical and Experimental Medicine, Unit of Endocrinology, University of Messina, Messina, Italy.
  5. Accademia Peloritana dei Pericolanti, University of Messina, Messina, Italy.

PMID: 29707123 PMCID: PMC5915131 DOI: 10.18632/oncotarget.24766

Abstract

BACKGROUND: Differentiated thyroid cancer (DTC) work-up is based on (near)total-thyroidectomy plus thyroid remnant ablation (TRA) with 131-radioiodine in many patients, and long-life follow-up.

RESULTS: Post-therapeutic imaging revealed metastases in 82 out of 570 (14.4%) patients. Metastases were successively confirmed by other diagnostic tools or by histology (sensitivity and PPV = 100%). Seventy-three out of 82 patients (90.2%) showed ps-Tg levels ≤1 ng/ml. In fifty-four per cent of patients, serum Tg levels at TRA remained ≤1 ng/ml.

CONCLUSION: In conclusion, ps-Tg levels cannot be used in deciding for or against TRA. In early stage of DTC, post-therapeutic imaging (

METHODS: We retrospectively reviewed the records of 570 consecutive patients affected by pT1-pT3 DTC (F = 450, M = 120), referred to our Nuclear Medicine Units in the last five years to perform TRA after (near)-total-thyroidectomy.All patients underwent TRA 3-4 months after thyroid surgery either in euthyroid or in hypothyroid state. Serum Tg values evaluated in post-surgical period and at TRA were matched with post-therapeutic imaging results.

Keywords: 131-radioiodine thyroid remnant ablation; 131-radioiodine treatment; differentiated thyroid cancer; post-therapy whole body scintigraphy; thyroglobulin

Conflict of interest statement

CONFLICTS OF INTEREST None.

References

  1. Endocrine. 2013 Oct;44(2):426-33 - PubMed
  2. Thyroid. 2013 Apr;23 (4):436-42 - PubMed
  3. Eur J Endocrinol. 2008 Jan;158(1):77-83 - PubMed
  4. Thyroid. 2014 Nov;24(11):1607-11 - PubMed
  5. Clin Chem Lab Med. 2009;47(8):1001-4 - PubMed
  6. J Cancer Epidemiol. 2013;2013:965212 - PubMed
  7. Thyroid. 2011 Jan;21(1):49-53 - PubMed
  8. JAMA. 2006 May 10;295(18):2164-7 - PubMed
  9. Eur J Nucl Med. 1990;16(1):35-8 - PubMed
  10. Eur J Endocrinol. 2011 Sep;165(3):441-6 - PubMed
  11. Clin Endocrinol (Oxf). 2007 Sep;67(3):434-41 - PubMed
  12. Eur J Nucl Med. 1999 Nov;26(11):1448-52 - PubMed
  13. Cancer. 1988 Mar 1;61(5):976-81 - PubMed
  14. Acta Endocrinol (Copenh). 1981 Oct;98(2):222-6 - PubMed
  15. Laryngoscope. 2005 Feb;115(2):264-7 - PubMed
  16. Clin Nucl Med. 1999 May;24(5):346-9 - PubMed
  17. Clin Chem. 2002 Jul;48(7):1077-83 - PubMed
  18. Thyroid. 2007 Nov;17(11):1085-92 - PubMed
  19. Thyroid. 2016 Jan;26(1):1-133 - PubMed
  20. Nucl Med Commun. 2010 Apr;31(4):274-9 - PubMed
  21. Eur J Nucl Med Mol Imaging. 2013 Jul;40(7):1126-34 - PubMed
  22. CA Cancer J Clin. 2013 Jan;63(1):11-30 - PubMed
  23. Eur J Endocrinol. 2016 Nov;175(5):R185-202 - PubMed
  24. Thyroid. 2002 Aug;12 (8):707-11 - PubMed
  25. Clin Nucl Med. 2011 Feb;36(2):109-12 - PubMed
  26. Eur J Nucl Med Mol Imaging. 2009 Feb;36(2):172-9 - PubMed
  27. Eur J Endocrinol. 2012 Dec;167(6):793-7 - PubMed
  28. Clin Endocrinol (Oxf). 2016 Jan;84(1):152-3 - PubMed
  29. Cancer. 1984 Oct 15;54(8):1625-8 - PubMed
  30. Ann Surg. 2003 Mar;237(3):399-407 - PubMed
  31. Clin Endocrinol (Oxf). 2008 Mar;68(3):338-42 - PubMed
  32. Clin Chem Lab Med. 2006;44(5):648-52 - PubMed
  33. Cancer. 2009 Aug 15;115(16):3801-7 - PubMed

Publication Types